JHL Biotech, an emerging biosimilars company in Taiwan, recently hosted a delegation of Brazilian government officials and top-ranking biotech executives who visited the company’s headquarters in support of Brazil’s partnership with JHL to produce affordable, world-class biosimilars.
The delegation included Antonio Werneck, president of In Vitro Brazil, Augusto Raupp, president of the Research Foundation of the State of Rio de Janeiro (FAPERJ), Joao Transmontano, CEO of Biolotus Biotech, and Tande Vieira, undersecretary of State of Science, Technology and Innovation and coordinator of the Executive Group of Life Sciences of the Industrial Complex of Rio de Janeiro.
Brazil has become an increasingly attractive target for biosimilar developers such as JHL because the government strongly supports its domestic manufacturers in working with international partners.
The delegation visited JHL’s state-of-the-art research and manufacturing facilities, which have been expanded in the last year to include dedicated formulation and molecular cell biology laboratories.
The delegation also had the opportunity to observe GMP production activities in JHL’s cGMP manufacturing plant, which earlier this year successfully released its first CMO drug substance batch in Taiwan and passed Australian inspection. The Taiwan plant complements JHL’s “big brother” cGMP facility in Wuhan, China, which when completed in 2015, will be the largest mammalian manufacturing plant of its kind in China.
